Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy
Learn More About Aimmune
Innovative medicines for the treatment of hormonally-driven cancers.
Aisling congratulates the management teams of Aragon and Seragon on their recent acquisitions by Johnson & Johnson and Genentech, respectively.
learn moreLearn More About Aragon & Seragon
CoolSculpting®: more science, less fat.
Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.
Learn More About Zeltiq
Largest provider of biopharmaceutical development and commercial outsourcing services.
Learn More About Quintiles
Dalvance™ for the treatment of acute bacterial skin and skin structure infections.
Aisling congratulates the management team of Durata on its recent acquisition by Actavis.
Learn More About Durata
Diagnostics to accurately identify sepsis pathogens in hours instead of days.
Learn More About T2 BiosystemsAisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.
See Our Portfolio
$1.8 billion in assets, with a track record of investing and returning capital since 2000.
learn moreLatest News
ADMA Biologics Receives PDUFA Date for BIVIGAM® Regulatory Submission
July 26, 2018
RAMSEY, N.J. and BOCA RATON, Fla., July 26, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that manufactures, markets and…
READ MORE
Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante Therapeutics
July 24, 2018
DUBLIN, Ireland, KING OF PRUSSIA, Pa. and SAN DIEGO, July 24, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development…
READ MORE
ViewRay Appoints Scott Drake as President, Chief Executive Officer and a Member of the Board of Directors, Shar Matin as Chief Operating Officer, and D. Keith Grossman as a Member of the Board of Directors
July 24, 2018
CLEVELAND, July 24, 2018 — ViewRay, Inc. (Nasdaq: VRAY), maker of the market-leading MRI-guided radiation therapy system,announced today the appointment of medical device industry veterans Scott Drake as its President…
READ MORE